Brief: Organon Announces US FDA Approval Of Supplemental New Drug Application Extending Duration Of Use Of Nexplanon® 68 Mg Radiopaque
17/01/2026 02:14
Jan 16 (Reuters) - Organon & Co OGN.N: ORGANON ANNOUNCES US FOOD AND DRUG ADMINISTRATION APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION EXTENDING DURATION OF USE OF NEXPLANON® (ETONOGESTREL IMPLANT) 68 MG RADIOPAQUE ORGANON & CO - NEXPLANON USE EXTENDED TO FIVE YEARS Source text: ID:nBw6MtY47a Further company coverage: OGN.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Organon & Co.
See all newsIndia's Sun Pharma misses debt fundraise goal as investors demand higher yields, bankers say
Brief: Organon & Co Says It Does Not Expect To Record Milestone Expense In Q3 2026
India's Persistent Systems plans debut rupee debt sale to fund acquisition, bankers say
India's Sun Pharma plans $1 billion local debt sale for loan takeout, sources say
Organon & Co reports results for the quarter ended June 30 - Earnings Summary